Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 ...

Fintel reports that on January 30, 2025, Chardan Capital downgraded their outlook for CARGO Therapeutics (NasdaqGS:CRGX) from ...

CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) was downgraded by stock analysts at Chardan Capital from a “buy” rating to ...

In a challenging market environment, shares of Chardan Nextech Acquisition 2 (DFLI) have reached a 52-week low, dipping to $2.13. The company, which has been navigating through a turbulent financial ...

Chardan analyst Geulah Livshits downgraded Editas Medicine (EDIT) to Neutral from Buy and withdrew the firm’s price target after the company announced a strategic transition to focus entirely on ...

Chardan downgraded CervoMed (CRVO) to Neutral from Buy without a price target after the company announced topline data from the Phase 2b RewinD-LB of neflamapimod, its only clinical stage asset ...

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.

Along with the evaluation of strategic alternatives, Eyenovia continues to progress development of its advanced Optejet device and is exploring options for use as both a consumer “user-filled” product ...